Obesity
Conditions
Interventions
Control group: 15 obese women with 25 (OH) D deficiency or insufficiency received 1 placebo capsule (matodextrin, 1g). Experimental group: 14 obese women with vitamin D deficiency or insufficiency, re
Dietary supplement
Sponsors
Universidade Federal da Paraíba
Universidade Federal da Paraíba
Eligibility
Sex/Gender
Female
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: women aged between 18 and 59 years; have vitamin D deficiency or insufficiency; have a Body Mass index greater than 25 kg / m²; do not take any vitamin D supplementation; not taking anticonvulsants or medications to treat the human immunodeficiency virus or acquired immunodeficiency syndrome; not having a diagnosis of Type I Diabetes Mellitus, nephrotic syndrome, acute or chronic kidney disease, liver disease, hypothyroidism, hyperthyroidism, history of stroke or acute myocardial infarction in the last 6 months; do not drink alcoholic beverages; do not smoke
Exclusion criteria
Exclusion criteria: Women with previous vitamin D use; women under 18 or over 59; women using anticonvulsants or medications to treat the human immunodeficiency virus or acquired immunodeficiency syndrome; women diagnosed with Type I Diabetes Mellitus, nephrotic syndrome, acute or chronic kidney disease, liver disease, hypothyroidism, hyperthyroidism, history of stroke or acute myocardial infarction in the last 6 months; Alcoholic women; smoking women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess serum vitamin D levels after vitamin D3 megadose supplementation. It is expected to find increased serum levels after 4 weeks of supplementation. Serum vitamin D levels were assessed by chemiluminescent immunoassay. A significant increase in serum vitamin D levels was observed from 23.8 IU pre-intervention to 31.7 IU after intervention (p 0.05). | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate serum markers of inflammation and oxidative stress after vitamin D3 megadose supplementation. It is expected to find serum levels of inflammatory markers and reduced oxidative stress after 4 weeks of supplementation. Serum levels of c-reactive protein and alpha glycoprotein were assessed by the immunoturbidimetric method. Oxidative stress was investigated by analyzing the total antioxidant capacity (TAC) using the 2,2-diphenyl-1-picrilhidrazil (DPPH) and lipid peroxidation method based on substances reactive to thiobarbituric acid (TBARS) with a spectrophotometric test. . There was no change in serum levels of c-reactive protein between pre and post-intervention in the placebo group (pre: 5.23 vs. post: 5.81, p> 0.05) or intervention (pre: 4.2 vs. post: 6.03, p> 0.05) . Similarly, alpha glycoprotein was not altered in the placebo group (pre: 96.5 vs. post: 87.5, p> 0.05) and in the intervention group (pre: 96.2 vs. post: 90.8, p> 0.05). Regarding the measures of oxidative stress, the total antioxidant capacity was similar in the placebo (pre: 26.9 vs. post: 26.7, p> 0.05) and in the intervention group (pre: 20.8 vs. post: 24.2, p> 0.05). However, lipid peroxidation levels did not change in the placebo group (pre: 2.8 vs. post: 3.1, p> 0.05), but increased in the intervention group (pre: 2.7 vs. post: 3.5, p <0.05). | — |
Countries
Brazil
Contacts
Public ContactJosé Luiz Alves
Universidade Federal da Paraíba
Outcome results
None listed